دورية أكاديمية
أعرض في EDS

Rapid platelet turnover in WASP(-) mice correlates with increased ex vivo phagocytosis of opsonized WASP(-) platelets.

التفاصيل البيبلوغرافية
العنوان: Rapid platelet turnover in WASP(-) mice correlates with increased ex vivo phagocytosis of opsonized WASP(-) platelets.
المؤلفون: Prislovsky A; Department of Pathology and Laboratory Medicine, Memphis Veterans Administration Medical Center, Memphis, TN 38104, USA., Marathe B, Hosni A, Bolen AL, Nimmerjahn F, Jackson CW, Weiman D, Strom TS
المصدر: Experimental hematology [Exp Hematol] 2008 May; Vol. 36 (5), pp. 609-23. Date of Electronic Publication: 2008 Mar 17.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Inc Country of Publication: Netherlands NLM ID: 0402313 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0301-472X (Print) Linking ISSN: 0301472X NLM ISO Abbreviation: Exp Hematol Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : Amsterdam : Elsevier Science Inc.
Original Publication: Copenhagen, Munksgaard.
مواضيع طبية MeSH: Blood Platelets/*immunology , Phagocytosis/*immunology , Thrombocytopenia/*immunology , Wiskott-Aldrich Syndrome/*immunology , Wiskott-Aldrich Syndrome Protein/*blood, Animals ; Antibodies/blood ; Antibodies/immunology ; Disease Models, Animal ; Female ; Flow Cytometry ; Fluoresceins/chemistry ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Opsonin Proteins/immunology ; Platelet Count ; Time Factors ; Wiskott-Aldrich Syndrome/genetics ; Wiskott-Aldrich Syndrome Protein/deficiency ; Wiskott-Aldrich Syndrome Protein/genetics
مستخلص: Objective: Our objective was to determine a mechanism for the thrombocytopenia of murine Wiskott-Aldrich syndrome (WAS).
Materials and Methods: Consumption rates of WAS protein (WASP)(-) and wild-type (WT) platelets were measured by injection of 5-chloromethylfluorescein diacetate (CMFDA)-labeled platelets into WT or WASP(-) recipients, and by in vivo biotinylation. Platelet and reticulated platelet counts were performed using quantitative flow cytometry. Bone marrow megakaryocyte number and ploidy was assessed by flow cytometry. Phagocytosis of CMFDA-labeled, opsonized platelets was assessed using bone marrow-derived macrophages. Serum antiplatelet antibodies were assayed via their binding to WT platelets.
Results: CMFDA-labeled WASP(-) platelets are consumed more rapidly than WT platelets in either WT or WASP(-) recipients. In vivo biotinylation studies corroborate these findings and show a normal consumption rate for WASP(-) reticulated platelets. The number of reticulated platelets is reduced in WASP(-) mice, but a significant number of the mice show an increased proportion of reticulated platelets and more severe thrombocytopenia. Sera from some of the latter group contain antiplatelet antibodies. Compared to WT platelets, WASP(-) platelets opsonized with anti-CD61 or 6A6 antibody are taken up more rapidly by bone marrow-derived macrophages. In vivo consumption rates of WASP(-) platelets are more accelerated by opsonization than are those of WT platelets.
Conclusion: Both rapid clearance and impaired production contribute to the thrombocytopenia of murine WAS. Increased susceptibility of opsonized WASP(-) platelets to phagocytosis leads to increased in vivo clearance. This correlates with a higher incidence of individuals with an elevated fraction of reticulated platelets, a more severe thrombocytopenia, and antiplatelet antibodies.
التعليقات: Erratum in: Exp Hematol. 2008 Jul;36(7):907.
References: Blood. 2000 May 1;95(9):2943-6. (PMID: 10779443)
Am J Clin Pathol. 1992 Dec;98(6):637-46. (PMID: 1281383)
Blood. 1990 Sep 1;76(5):859-70. (PMID: 2203482)
Blood. 1986 Feb;67(2):343-9. (PMID: 2935208)
Blood. 1999 Dec 15;94(12):4166-76. (PMID: 10590061)
Blood. 1997 Feb 1;89(3):823-33. (PMID: 9028313)
J Pediatr Hematol Oncol. 2003 Dec;25 Suppl 1:S57-61. (PMID: 14668642)
Blood. 1999 Jul 15;94(2):509-18. (PMID: 10397718)
Exp Hematol. 1995 Aug;23(9):996-1001. (PMID: 7635185)
Blood. 2004 Dec 15;104(13):4010-9. (PMID: 15284122)
J Pediatr. 1994 Dec;125(6 Pt 1):876-85. (PMID: 7996359)
Br J Haematol. 1997 Jun;97(4):747-54. (PMID: 9217172)
Blood. 2000 Feb 1;95(3):1110-1. (PMID: 10691337)
Thromb Haemost. 2001 Aug;86(2):668-71. (PMID: 11522020)
Curr Opin Rheumatol. 2003 Jul;15(4):446-53. (PMID: 12819473)
Blood. 1985 Jun;65(6):1439-43. (PMID: 3995178)
Br J Haematol. 1999 Sep;106(4):875-83. (PMID: 10519987)
Arch Dis Child. 1996 Nov;75(5):436-9. (PMID: 8957959)
Pediatrics. 1954 Feb;13(2):133-9. (PMID: 13133561)
Blood. 1980 Feb;55(2):243-52. (PMID: 6444359)
Blood. 2005 May 1;105(9):3577-82. (PMID: 15665111)
Blood. 2002 Sep 15;100(6):2113-22. (PMID: 12200375)
Br J Haematol. 1969 Oct;17(4):373-88. (PMID: 5346410)
Blood. 2000 Feb 15;95(4):1283-92. (PMID: 10666201)
Semin Immunol. 2004 Dec;16(6):395-407. (PMID: 15541654)
Blood. 2006 May 15;107(10):3868-75. (PMID: 16434494)
Ann N Y Acad Sci. 1972 Oct 27;201:437-44. (PMID: 4265132)
Am J Hematol. 1991 Aug;37(4):274-6. (PMID: 1858787)
Thromb Haemost. 1987 Oct 28;58(3):866-71. (PMID: 3433250)
Immunity. 2006 Aug;25(2):285-95. (PMID: 16901726)
Methods Enzymol. 1992;215:420-7. (PMID: 1435339)
N Engl J Med. 1972 Mar 9;286(10):499-504. (PMID: 5062078)
Immunity. 1998 Jul;9(1):81-91. (PMID: 9697838)
J Biol Chem. 1977 Aug 25;252(16):5602-5. (PMID: 885868)
Blood. 2004 Oct 1;104(7):2102-6. (PMID: 15205264)
Br J Haematol. 2000 Mar;108(4):859-64. (PMID: 10792296)
Blood. 2006 Jul 1;108(1):134-40. (PMID: 16522820)
J Biol Chem. 2007 Nov 23;282(47):34194-203. (PMID: 17890224)
Blood. 2002 May 15;99(10):3500-4. (PMID: 11986200)
Blood. 2004 Dec 1;104(12):3454-62. (PMID: 15308573)
Exp Hematol. 2005 Apr;33(4):443-51. (PMID: 15781335)
Br J Haematol. 2000 Feb;108(2):228-35. (PMID: 10691847)
Exp Hematol. 1997 Sep;25(10):1019-24. (PMID: 9293898)
Blood. 1993 Aug 1;82(3):837-44. (PMID: 8338948)
Science. 2006 Aug 4;313(5787):670-3. (PMID: 16888140)
Blood. 1985 Nov;66(5):1105-9. (PMID: 4052629)
Br J Haematol. 1999 Nov;107(2):254-62. (PMID: 10583210)
Blood. 2002 Mar 15;99(6):2268-9. (PMID: 11877312)
Blood. 2002 Jun 15;99(12):4626-8. (PMID: 12036897)
Blood. 1993 Nov 15;82(10):2961-6. (PMID: 8219187)
Blood. 1998 Dec 1;92(11):4446-52. (PMID: 9834252)
J Immunol. 2001 Apr 15;166(8):4831-4. (PMID: 11290758)
J Exp Med. 1999 Nov 1;190(9):1329-42. (PMID: 10544204)
J Exp Med. 1988 Jun 1;167(6):2017-22. (PMID: 3290385)
Mol Biol Cell. 1997 Sep;8(9):1709-21. (PMID: 9307968)
EMBO Rep. 2004 Sep;5(9):895-900. (PMID: 15332112)
Blood. 1995 Apr 1;85(7):1822-5. (PMID: 7535589)
معلومات مُعتمدة: R21 AI079757 United States AI NIAID NIH HHS; K08 HL072865-05 United States HL NHLBI NIH HHS; K08 HL072865 United States HL NHLBI NIH HHS; K08 HL072865-06 United States HL NHLBI NIH HHS; 1 K08 HL72865-01A1 United States HL NHLBI NIH HHS
المشرفين على المادة: 0 (Antibodies)
0 (Fluoresceins)
0 (Opsonin Proteins)
0 (Was protein, mouse)
0 (Wiskott-Aldrich Syndrome Protein)
136832-63-8 (5-chloromethylfluorescein)
تواريخ الأحداث: Date Created: 20080319 Date Completed: 20080905 Latest Revision: 20211020
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC2635498
DOI: 10.1016/j.exphem.2007.12.019
PMID: 18346836
قاعدة البيانات: MEDLINE
الوصف
تدمد:0301-472X
DOI:10.1016/j.exphem.2007.12.019